O	0	1	A
O	2	12	randomized
O	13	23	comparison
O	24	26	of
B-intervention	27	35	sentinel
I-intervention	35	36	-
I-intervention	36	40	node
I-intervention	41	47	biopsy
O	48	52	with
B-control	53	60	routine
I-control	61	69	axillary
I-control	70	80	dissection
O	81	83	in
O	84	90	breast
O	91	97	cancer
O	97	98	.

O	99	107	Although
O	108	116	numerous
O	117	124	studies
O	125	129	have
O	130	135	shown
O	136	140	that
O	141	144	the
O	145	151	status
O	152	154	of
O	155	158	the
O	159	167	sentinel
O	168	172	node
O	173	175	is
O	176	178	an
O	179	187	accurate
O	188	197	predictor
O	198	200	of
O	201	204	the
O	205	211	status
O	212	214	of
O	215	218	the
O	219	227	axillary
O	228	233	nodes
O	234	236	in
O	237	243	breast
O	244	250	cancer
O	250	251	,
O	252	255	the
O	256	264	efficacy
O	265	268	and
O	269	275	safety
O	276	278	of
O	279	287	sentinel
O	287	288	-
O	288	292	node
O	293	299	biopsy
O	300	307	require
O	308	318	validation
O	318	319	.

O	320	324	From
O	325	330	March
O	331	335	1998
O	336	338	to
O	339	347	December
O	348	352	1999
O	352	353	,
O	354	356	we
O	357	365	randomly
O	366	374	assigned
B-total-participants	375	378	516
B-eligibility	379	387	patients
I-eligibility	388	392	with
I-eligibility	393	400	primary
I-eligibility	401	407	breast
I-eligibility	408	414	cancer
I-eligibility	415	417	in
I-eligibility	418	422	whom
I-eligibility	423	426	the
I-eligibility	427	432	tumor
I-eligibility	433	436	was
I-eligibility	437	441	less
I-eligibility	442	446	than
I-eligibility	447	449	or
I-eligibility	450	455	equal
I-eligibility	456	458	to
I-eligibility	459	460	2
I-eligibility	461	463	cm
I-eligibility	464	466	in
I-eligibility	467	475	diameter
O	476	482	either
O	483	485	to
O	486	494	sentinel
O	494	495	-
O	495	499	node
O	500	506	biopsy
O	507	510	and
O	511	516	total
O	517	525	axillary
O	526	536	dissection
O	537	538	(
O	538	541	the
O	542	550	axillary
O	550	551	-
O	551	561	dissection
O	562	567	group
O	567	568	)
O	569	571	or
O	572	574	to
O	575	583	sentinel
O	583	584	-
O	584	588	node
O	589	595	biopsy
O	596	604	followed
O	605	607	by
O	608	616	axillary
O	617	627	dissection
O	628	632	only
O	633	635	if
O	636	639	the
O	640	648	sentinel
O	649	653	node
O	654	663	contained
O	664	674	metastases
O	675	676	(
O	676	679	the
O	680	688	sentinel
O	688	689	-
O	689	693	node
O	694	699	group
O	699	700	)
O	700	701	.

O	702	705	The
B-outcome	706	712	number
I-outcome	713	715	of
I-outcome	716	724	sentinel
I-outcome	725	730	nodes
O	731	736	found
O	737	740	was
O	741	744	the
O	745	749	same
O	750	752	in
O	753	756	the
O	757	760	two
O	761	767	groups
O	767	768	.

O	769	770	A
B-outcome	771	779	sentinel
I-outcome	780	784	node
I-outcome	785	788	was
I-outcome	789	797	positive
O	798	800	in
B-cv-bin-abs	801	803	83
O	804	806	of
O	807	810	the
B-control-participants	811	814	257
O	815	823	patients
O	824	826	in
O	827	830	the
O	831	839	axillary
O	839	840	-
O	840	850	dissection
O	851	856	group
O	857	858	(
B-cv-bin-percent	858	860	32
I-cv-bin-percent	860	861	.
I-cv-bin-percent	861	862	3
I-cv-bin-percent	863	870	percent
O	870	871	)
O	871	872	,
O	873	876	and
O	877	879	in
B-iv-bin-abs	880	882	92
O	883	885	of
O	886	889	the
B-intervention-participants	890	893	259
O	894	902	patients
O	903	905	in
O	906	909	the
O	910	918	sentinel
O	918	919	-
O	919	923	node
O	924	929	group
O	930	931	(
B-iv-bin-percent	931	933	35
I-iv-bin-percent	933	934	.
I-iv-bin-percent	934	935	5
I-iv-bin-percent	936	943	percent
O	943	944	)
O	944	945	.

O	946	948	In
O	949	952	the
O	953	961	axillary
O	961	962	-
O	962	972	dissection
O	973	978	group
O	978	979	,
O	980	983	the
B-outcome	984	991	overall
I-outcome	992	1000	accuracy
I-outcome	1001	1003	of
I-outcome	1004	1007	the
I-outcome	1008	1016	sentinel
I-outcome	1016	1017	-
I-outcome	1017	1021	node
I-outcome	1022	1028	status
O	1029	1032	was
B-cv-bin-percent	1033	1035	96
I-cv-bin-percent	1035	1036	.
I-cv-bin-percent	1036	1037	9
I-cv-bin-percent	1038	1045	percent
O	1045	1046	,
O	1047	1050	the
B-outcome	1051	1062	sensitivity
B-cv-bin-percent	1063	1065	91
I-cv-bin-percent	1065	1066	.
I-cv-bin-percent	1066	1067	2
I-cv-bin-percent	1068	1075	percent
O	1075	1076	,
O	1077	1080	and
O	1081	1084	the
B-outcome	1085	1096	specificity
B-cv-bin-percent	1097	1100	100
I-cv-bin-percent	1101	1108	percent
O	1108	1109	.

O	1110	1115	There
O	1116	1119	was
O	1120	1124	less
B-outcome	1125	1129	pain
O	1130	1133	and
O	1134	1140	better
B-outcome	1141	1144	arm
I-outcome	1145	1153	mobility
O	1154	1156	in
O	1157	1160	the
O	1161	1169	patients
O	1170	1173	who
O	1174	1183	underwent
O	1184	1192	sentinel
O	1192	1193	-
O	1193	1197	node
O	1198	1204	biopsy
O	1205	1209	only
O	1210	1214	than
O	1215	1217	in
O	1218	1223	those
O	1224	1227	who
O	1228	1232	also
O	1233	1242	underwent
O	1243	1251	axillary
O	1252	1262	dissection
O	1262	1263	.

O	1264	1269	There
O	1270	1274	were
B-cv-bin-abs	1275	1277	15
B-outcome	1278	1284	events
I-outcome	1285	1295	associated
I-outcome	1296	1300	with
I-outcome	1301	1307	breast
I-outcome	1308	1314	cancer
O	1315	1317	in
O	1318	1321	the
O	1322	1330	axillary
O	1330	1331	-
O	1331	1341	dissection
O	1342	1347	group
O	1348	1351	and
B-iv-bin-abs	1352	1354	10
O	1355	1359	such
O	1360	1366	events
O	1367	1369	in
O	1370	1373	the
O	1374	1382	sentinel
O	1382	1383	-
O	1383	1387	node
O	1388	1393	group
O	1393	1394	.

O	1395	1400	Among
O	1401	1404	the
O	1405	1408	167
O	1409	1417	patients
O	1418	1421	who
O	1422	1425	did
O	1426	1429	not
O	1430	1437	undergo
O	1438	1446	axillary
O	1447	1457	dissection
O	1457	1458	,
O	1459	1464	there
O	1465	1469	were
O	1470	1472	no
B-outcome	1473	1478	cases
I-outcome	1479	1481	of
I-outcome	1482	1487	overt
I-outcome	1488	1496	axillary
I-outcome	1497	1507	metastasis
O	1508	1514	during
O	1515	1521	follow
O	1521	1522	-
O	1522	1524	up
O	1524	1525	.

O	1526	1534	Sentinel
O	1534	1535	-
O	1535	1539	node
O	1540	1546	biopsy
O	1547	1549	is
O	1550	1551	a
O	1552	1556	safe
O	1557	1560	and
O	1561	1569	accurate
O	1570	1576	method
O	1577	1579	of
O	1580	1589	screening
O	1590	1593	the
O	1594	1602	axillary
O	1603	1608	nodes
O	1609	1612	for
O	1613	1623	metastasis
O	1624	1626	in
O	1627	1632	women
O	1633	1637	with
O	1638	1639	a
O	1640	1645	small
O	1646	1652	breast
O	1653	1659	cancer
O	1659	1660	.
